Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis

Relationship of levels of autoantibodies to disease progression

Michael D. Van Norstrand, Michael Malinchoc, Keith D. Lindor, Terry M Therneau, M. Eric Gershwin, Patrick S C Leung, E. Rolland Dickson, Henry A. Homburger

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

We examined the clinical usefulness of measurements of antimitochondrial autoantibodies (AMA) in predicting disease progression in patients with primary biliary cirrhosis (PBC). We determined the relationships between AMA levels measured by indirect immunofluorescence (IF) and those measured by quantitative enzyme immunoassays (EIAs) using recombinant 2-oxo-acid dehydrogenase complex (2-OADC) proteins and the Mayo Risk Score, an established indicator of disease progression in primary biliary cirrhosis (PBC). Results of tests for AMA by either method correlated weakly (r = .24 to .30) with disease progression as indicated by Mayo Risk Scores. The levels of AMA to 2-OADC proteins varied by more than 200-fold between patients but remained relatively constant over time in individual patients. Despite being positively correlated with Mayo Risk Score results, the levels of AMA to 2- OADC proteins were not useful for predicting disease progression in individual patients with PBC. In addition, we found no significant differences in the levels of autoantibodies to 2-OADC proteins among patients with different histological stages of disease. Our results show that measurements of AMA by IF or by quantitative EIA methods with recombinant 2- OADC proteins are not useful parameters for predicting disease progression in patients with PBC.

Original languageEnglish (US)
Pages (from-to)6-11
Number of pages6
JournalHepatology
Volume25
Issue number1
StatePublished - Jan 1997

Fingerprint

Biliary Liver Cirrhosis
Autoantibodies
Disease Progression
Antigens
Keto Acids
Oxidoreductases
Proteins
Immunoenzyme Techniques
Indirect Fluorescent Antibody Technique
Fluorescent Antibody Technique

ASJC Scopus subject areas

  • Hepatology

Cite this

Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis : Relationship of levels of autoantibodies to disease progression. / Van Norstrand, Michael D.; Malinchoc, Michael; Lindor, Keith D.; Therneau, Terry M; Gershwin, M. Eric; Leung, Patrick S C; Dickson, E. Rolland; Homburger, Henry A.

In: Hepatology, Vol. 25, No. 1, 01.1997, p. 6-11.

Research output: Contribution to journalArticle

Van Norstrand, Michael D. ; Malinchoc, Michael ; Lindor, Keith D. ; Therneau, Terry M ; Gershwin, M. Eric ; Leung, Patrick S C ; Dickson, E. Rolland ; Homburger, Henry A. / Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis : Relationship of levels of autoantibodies to disease progression. In: Hepatology. 1997 ; Vol. 25, No. 1. pp. 6-11.
@article{38dd824f77384424afeaa67a401d54bd,
title = "Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: Relationship of levels of autoantibodies to disease progression",
abstract = "We examined the clinical usefulness of measurements of antimitochondrial autoantibodies (AMA) in predicting disease progression in patients with primary biliary cirrhosis (PBC). We determined the relationships between AMA levels measured by indirect immunofluorescence (IF) and those measured by quantitative enzyme immunoassays (EIAs) using recombinant 2-oxo-acid dehydrogenase complex (2-OADC) proteins and the Mayo Risk Score, an established indicator of disease progression in primary biliary cirrhosis (PBC). Results of tests for AMA by either method correlated weakly (r = .24 to .30) with disease progression as indicated by Mayo Risk Scores. The levels of AMA to 2-OADC proteins varied by more than 200-fold between patients but remained relatively constant over time in individual patients. Despite being positively correlated with Mayo Risk Score results, the levels of AMA to 2- OADC proteins were not useful for predicting disease progression in individual patients with PBC. In addition, we found no significant differences in the levels of autoantibodies to 2-OADC proteins among patients with different histological stages of disease. Our results show that measurements of AMA by IF or by quantitative EIA methods with recombinant 2- OADC proteins are not useful parameters for predicting disease progression in patients with PBC.",
author = "{Van Norstrand}, {Michael D.} and Michael Malinchoc and Lindor, {Keith D.} and Therneau, {Terry M} and Gershwin, {M. Eric} and Leung, {Patrick S C} and Dickson, {E. Rolland} and Homburger, {Henry A.}",
year = "1997",
month = "1",
language = "English (US)",
volume = "25",
pages = "6--11",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis

T2 - Relationship of levels of autoantibodies to disease progression

AU - Van Norstrand, Michael D.

AU - Malinchoc, Michael

AU - Lindor, Keith D.

AU - Therneau, Terry M

AU - Gershwin, M. Eric

AU - Leung, Patrick S C

AU - Dickson, E. Rolland

AU - Homburger, Henry A.

PY - 1997/1

Y1 - 1997/1

N2 - We examined the clinical usefulness of measurements of antimitochondrial autoantibodies (AMA) in predicting disease progression in patients with primary biliary cirrhosis (PBC). We determined the relationships between AMA levels measured by indirect immunofluorescence (IF) and those measured by quantitative enzyme immunoassays (EIAs) using recombinant 2-oxo-acid dehydrogenase complex (2-OADC) proteins and the Mayo Risk Score, an established indicator of disease progression in primary biliary cirrhosis (PBC). Results of tests for AMA by either method correlated weakly (r = .24 to .30) with disease progression as indicated by Mayo Risk Scores. The levels of AMA to 2-OADC proteins varied by more than 200-fold between patients but remained relatively constant over time in individual patients. Despite being positively correlated with Mayo Risk Score results, the levels of AMA to 2- OADC proteins were not useful for predicting disease progression in individual patients with PBC. In addition, we found no significant differences in the levels of autoantibodies to 2-OADC proteins among patients with different histological stages of disease. Our results show that measurements of AMA by IF or by quantitative EIA methods with recombinant 2- OADC proteins are not useful parameters for predicting disease progression in patients with PBC.

AB - We examined the clinical usefulness of measurements of antimitochondrial autoantibodies (AMA) in predicting disease progression in patients with primary biliary cirrhosis (PBC). We determined the relationships between AMA levels measured by indirect immunofluorescence (IF) and those measured by quantitative enzyme immunoassays (EIAs) using recombinant 2-oxo-acid dehydrogenase complex (2-OADC) proteins and the Mayo Risk Score, an established indicator of disease progression in primary biliary cirrhosis (PBC). Results of tests for AMA by either method correlated weakly (r = .24 to .30) with disease progression as indicated by Mayo Risk Scores. The levels of AMA to 2-OADC proteins varied by more than 200-fold between patients but remained relatively constant over time in individual patients. Despite being positively correlated with Mayo Risk Score results, the levels of AMA to 2- OADC proteins were not useful for predicting disease progression in individual patients with PBC. In addition, we found no significant differences in the levels of autoantibodies to 2-OADC proteins among patients with different histological stages of disease. Our results show that measurements of AMA by IF or by quantitative EIA methods with recombinant 2- OADC proteins are not useful parameters for predicting disease progression in patients with PBC.

UR - http://www.scopus.com/inward/record.url?scp=0031029761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031029761&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 6

EP - 11

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -